See more : Pharmacolog i Uppsala AB (publ) (PHLOG-B.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Tyra Biosciences, Inc. (TYRA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tyra Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Xinjiang Talimu Agriculture Development Co., Ltd. (600359.SS) Income Statement Analysis – Financial Results
- Yufo Electronics Co., Ltd. (6194.TWO) Income Statement Analysis – Financial Results
- Gallantt Ispat Limited (GALLISPAT.NS) Income Statement Analysis – Financial Results
- China Everbright Environment Group Limited (CHFFY) Income Statement Analysis – Financial Results
- Lockheed Martin Corporation (LMT.MX) Income Statement Analysis – Financial Results
Tyra Biosciences, Inc. (TYRA)
About Tyra Biosciences, Inc.
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 353.00K | 296.00K | 140.00K | 47.00K | 8.00K |
| Gross Profit | -353.00K | -296.00K | -140.00K | -47.00K | -8.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 62.52M | 43.01M | 20.64M | 7.20M | 1.79M |
| General & Administrative | 17.43M | 15.92M | 5.65M | 2.09M | 1.33M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 17.43M | 15.92M | 5.65M | 2.09M | 1.33M |
| Other Expenses | 0.00 | -50.00K | -19.00K | -23.00K | -8.00K |
| Operating Expenses | 79.95M | 58.93M | 26.29M | 9.30M | 3.12M |
| Cost & Expenses | 79.95M | 58.93M | 26.29M | 9.30M | 3.12M |
| Interest Income | 10.85M | 3.65M | 13.00K | 1.00 | 1.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 1.00K | 1.00K |
| Depreciation & Amortization | 353.00K | 296.00K | 140.00K | 47.00K | 8.00K |
| EBITDA | -79.59M | -58.63M | -26.15M | -9.25M | -3.11M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -79.95M | -58.93M | -26.29M | -9.30M | -3.12M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 10.81M | 3.60M | -6.00K | -39.00K | -943.00K |
| Income Before Tax | -69.13M | -55.33M | -26.29M | -9.34M | -4.07M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -3.60M | -153.00K | -22.00K | -7.00K |
| Net Income | -69.13M | -51.72M | -26.14M | -9.31M | -4.06M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.62 | -1.23 | -0.63 | -0.22 | -0.10 |
| EPS Diluted | -1.62 | -1.23 | -0.63 | -0.22 | -0.10 |
| Weighted Avg Shares Out | 42.70M | 41.88M | 41.44M | 42.54M | 42.54M |
| Weighted Avg Shares Out (Dil) | 42.70M | 41.88M | 41.44M | 42.54M | 42.54M |
The Schall Law Firm Is Looking Into Tyra Biosciences Inc For Possibly Violating Securities Laws And The Firm Seeks Shareholder Participation
LOS ANGELES, CA / ACCESSWIRE / September 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or "the Company") (NASDAQ:TYRA) for...
Tyra Biosciences to Present at the 2024 Cantor Global Healthcare Conference
CARLSBAD, Calif. , Sept. 11, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today its participation at the 2024...
Tyra Biosciences, Inc. May Have Defrauded Shareholders And Impacted Individuals Are Invited To Join The Schall Law Firm's Investigation
LOS ANGELES, CA / ACCESSWIRE / September 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or "the Company") (NASDAQ:TYRA) for...
Tyra Biosciences Appoints Doug Warner, M.D., as Chief Medical Officer
-Dr. Warner brings over twenty years of proven clinical development leadership to TYRA having successfully led global development and secured approvals for medicines across oncology and skeletal disease- CARLSBAD, Calif. , Sept. 10, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq:...
The Schall Law Firm Has Launched An Inquiry Into Tyra Biosciences Inc For Securities Law Violations And Investors Are Urged To Contribute
LOS ANGELES, CA / ACCESSWIRE / September 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or "the Company") (NASDAQ:TYRA) for...
Tyra Biosciences, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Wants Shareholders To Participate
LOS ANGELES, CA / ACCESSWIRE / September 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or "the Company") (NASDAQ:TYRA) for...
Wall Street Analysts Think Tyra Biosciences (TYRA) Could Surge 27.88%: Read This Before Placing a Bet
The consensus price target hints at a 27.9% upside potential for Tyra Biosciences (TYRA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an...
Fraudulent Practices May Have Been Committed By Tyra Biosciences Inc And Affected Investors Are Urged To Reach Out To The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / September 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or "the Company") (NASDAQ:TYRA) for...
Investors Are Invited By The Schall Law Firm To Partake In An Inquiry In Tyra Biosciences, Inc's Possible Violations Of Securities Regulations
LOS ANGELES, CA / ACCESSWIRE / September 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or "the Company") (NASDAQ:TYRA) for...
Tyra Biosciences, Inc. Is Being Looked Into For Acting Wrongfully And The Schall Law Firm Has Launched An Investigation That Shareholders Can Join
LOS ANGELES, CA / ACCESSWIRE / September 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or "the Company") (NASDAQ:TYRA) for...
Source: https://incomestatements.info
Category: Stock Reports